Uncategorized

Big Pharma–backed Coultreon bags $125M series A to unlock alternative immune pathway

Published

1 week ago

on

April 28, 2026

By

Temp User

Coultreon Biopharma is advancing assets that target salt-inducible kinases, proteins that drive inflammation and other immune-mediated conditions.

Related Topics:

Leave a Reply

Uncategorized9 years ago

These ’90s fashion trends are making a comeback in 2017
Contributors9 years ago

The final 6 ‘Game of Thrones’ episodes might feel like a full season
Uncategorized9 years ago

According to Dior Couture, this taboo fashion accessory is back
Uncategorized9 years ago

Uber and Lyft are finally available in all of New York State
Uncategorized9 years ago

Phillies’ Aaron Altherr makes mind-boggling barehanded play
Uncategorized9 years ago

The old and New Edition cast comes together to perform

Exit mobile version